St. Clair Advisors LLC Acquires Shares of 35,967 Pfizer Inc. (NYSE:PFE)

St. Clair Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 35,967 shares of the biopharmaceutical company's stock, valued at approximately $954,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group boosted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Price Performance

Pfizer stock opened at $22.83 on Monday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The stock has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. The firm's 50-day moving average is $23.65 and its two-hundred day moving average is $25.32. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the company earned $0.82 EPS. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.